AR035069A1 - Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento - Google Patents

Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento

Info

Publication number
AR035069A1
AR035069A1 ARP010104977A ARP010104977A AR035069A1 AR 035069 A1 AR035069 A1 AR 035069A1 AR P010104977 A ARP010104977 A AR P010104977A AR P010104977 A ARP010104977 A AR P010104977A AR 035069 A1 AR035069 A1 AR 035069A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
heteroaryl
independently selected
cycloalkyl
Prior art date
Application number
ARP010104977A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR035069A1 publication Critical patent/AR035069A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

Inhibidores de 5-espiropirimidin-2,4,6-triona metaloproteinasas de fórmula (1) en la que el citado "A" es un anillo heterocíclico de 5 a 7 miembros seleccionado del grupo constituido por las fórmulas (a) hasta (o) en las que cada uno de R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 y R13 se selecciona independientemente del grupo constituido por hidrógeno, alquilo C1-4, alquenilo C1-4, alquinilo C1-4, arilo C6-10, heteroarilo C1-10, cicloalquilo C3-8 y heterociclilo C1-10; pudiendo estar de los citados alquilo C1-4, arilo C6-10, heteroarilo C1-10, cicloalquilo C3-8 y heterociclilo C1-10 opcionalmente sustituido en cualquiera de los átomos de carbono del anillo capaces de formar un enlace adicional con 1 a 3 sustituyentes por anillo seleccionados independientemente de halo, alquilo C1-4, alcoxi C1-4, -CN, -OH y -NH2; X es arilo C6-10 ó heteroarilo C1-10; Y se selecciona del grupo constituido por un enlace, oxígeno, azufre, >C=O, >SO2, >S=O, -CH2-, -CH2O-, -O(CH2)n-, -CH2S-, -S(CH2)n-, -CH2SO-, -CH2SO2-, -SO(CH2)n-, -SO2(CH2)n-, -NR14, -NR14(CH2)n-, -CH2[N(R14)]-, CH2(CH2)n-, -CH=CH-, -C:::C-, -[N(R14)]-SO2- y -SO2[N(R14)]-;n es un entero de 1 a 4; R14 es hidrógeno o alquilo C1-4; Z se selecciona del grupo constituido por arilo C6-10, cicloalquilo C3-8, heterociclilo C1-10 y heteroarilo C1-10, pudiendo estar uno o dos enlaces sencillos carbono-carbono reemplazados por dobles enlaces carbono-carbono; pudiendo estar cada uno de los citados X ó Z sustituido opcional e independientemente en cualquiera de los átomos de carbono del anillo capaz de formar un enlace adicional con 1 ó 2 sustituyentes por anillo seleccionados independientemente de F, Cl, Br, CN, OH, alquilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4 y cicloalquil C3-8oxi; G es R15-(CR16R17)p-; siendo G un sustituyente en cualquier átomo de carbono del anillo de Z capaz de formar un enlace adicional y estando orientado en una posición distinta de alfa respecto del punto de unión del anillo Z a Y; p es un entero de 0 a 4; R15 se selecciona independientemente del grupo constituido por halo, -CN, -NO2, OH, alquenilo C1-4, alquinilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, R18-, R18-O-, R18-alquil C1-4-O-, R18-(C=O)-, R18-(C=O)-O-, R18-O-(C=O)-, R18-S-, R22-(S=O)-, R18-(SO2)-, R22-(SO2)-(NR21)-, R19-(C=O)-(NR21)-, R22-O-(C=O)-(NR21), (R19R20)N-, (R10R20)N-(SO2)-, (R19R20)N-(C=O)-, (R19R20)N-(C=O)-(NR21)- y (R19R20)N-(C=O)-O-; cada uno de R16 y R17 se selecciona independientemente de hidrógeno y alquilo C1-4; ó R16 y R17 pueden tomarse opcionalmente conjuntamente con el carbono al que están unidos para formar un anillo carbocíclico de 5 a 10 miembros; R18, R19, R20 y R21 se seleccionan independientemente del grupo constituido por hidrógeno, alquilo C1-4, arilo C6-10, cicloalquilo C3-8, heteroarilo C1-10 y heterociclilo C1-10; pudiendo estar los citados restos arilo C6-10, cicloalquilo C3-8, heteroarilo C1-10 y heterociclilo C1-10 opcionalmente sustituidos en cualquiera de los átomos de carbono del anillo capaces de formar un enlace adicional con 1 a 3 sustituyentes por anillo seleccionados independientemente de F, Cl, Br, CN, OH, alquilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4, amino, alquil C1-4-NH-, [alquil C1-4]2-N- y cicloalquil C3-8oxi; pudiendo estar los citados restos heteroarilo C1-10 y heterociclilo C1-10 opcionalmente sustituidos en cualquier átomo de nitrógeno capaz de soportar un sustituyente adicional con 1 ó 2 sustituyentes por anillo seleccionados independientemente del grupo constituido por alquilo C1-4 y alquil C1-4-(C=O)-; ó R19 y R20 pueden tomarse opcionalmente conjuntamente con el átomo de nitrógeno al que están unidos para format un anillo heterocíclico de 3 a 8 miembros; ó R19 y R21 pueden tomarse opcionalmente conjuntamente con el átomo de nitrógeno, de carbono, o de oxígeno al que están unidos para formar un anillo heterocíclico de 3 a 8 miembros; R22 se selecciona del grupo constituido por alquilo C1-4, arilo C6-10, cicloalquilo C3-8, heteroarilo C1-10 y heterociclilo C1-10; pudiendo estar los citados restos arilo C6-10, cicloalquilo C3-8, heteroarilo C1-10 y heterociclilo C1-10 opcionalmente sustituidos en cualquiera de los átomos de carbono del anillo capaces de formar un enlace adicional con 1 a 3 sustituyentes por anillo seleccionados independientemente de F, Cl, Br, CN, OH, alquilo C1-4, perfluoroalquilo C1-4, perfluoroalcoxi C1-4, alcoxi C1-4, amino, alquil C1-4-NH-, [alquil C1-4]2-N- y cicloalquil C3-8oxi; pudiendo estar los citados restos cicloalquilo C3-8 y heterociclilo C1-10 opcionalmente sustituidos con oxo; pudiendo estar los citados restos heteroarilo C1-10 y heterociclilo C1-10 en cualquier átomo de nitrógeno capaz de soportar un sustituyente adicional con 1 ó 2 sustituyentes por anillo seleccionados independientemente del grupo constituido por alquilo C1-4 y alquil C1-4-(C=O)-; ó R21 y R22 pueden tomarse opcionalmente conjuntamente con el átomo de nitrógeno, oxígeno o azufre al que están unidos para formar un anillo heterocíclico de 3 a 8 miembros; o una sal farmacéuticamente aceptable de éstos, y composiciones farmacéuticas y procedimientos de tratamiento de la inflamación, el cáncer y otras dolencias. Estos compuestos son ihbibidores de metaloendopeptidasas de zinc, especialmente aquellas que pertenecen al tipo de metaloproteinasas de matriz también llamadas MMP o matrixinas. Las composiciones farmacéuticas que contienen el compuesto son útiles en el tratamiento de dolencias del tejido conectivo, inflamatorias, inmunológicas/alérgicas, enfermedades infecciosas, respiratorias, cardiovasculares, oculares, metabólicas, trastornos del SNC, enfermedades hepáticas, renales, dolencias de la salud reproductiva, gástricas, de la piel y cánceres y otras enfermedades caracterizadas por la actividad metaloproteinasa en un mamífero incluyendo un humano.
ARP010104977A 2000-10-26 2001-10-24 Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento AR035069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24338900P 2000-10-26 2000-10-26

Publications (1)

Publication Number Publication Date
AR035069A1 true AR035069A1 (es) 2004-04-14

Family

ID=22918584

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104977A AR035069A1 (es) 2000-10-26 2001-10-24 Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento

Country Status (32)

Country Link
EP (1) EP1332146A2 (es)
JP (1) JP2004518635A (es)
KR (1) KR20040004412A (es)
CN (1) CN1501937A (es)
AP (1) AP2001002318A0 (es)
AR (1) AR035069A1 (es)
AU (1) AU2002210813A1 (es)
BG (1) BG107653A (es)
BR (1) BR0114913A (es)
CA (1) CA2425283A1 (es)
CZ (1) CZ20031083A3 (es)
EA (1) EA005762B1 (es)
EC (1) ECSP034567A (es)
EE (1) EE200300196A (es)
GT (1) GT200100213A (es)
HN (1) HN2001000244A (es)
HR (1) HRP20030332A2 (es)
HU (1) HUP0301577A3 (es)
IL (1) IL154948A0 (es)
IS (1) IS6762A (es)
MA (1) MA26957A1 (es)
MX (1) MXPA03003735A (es)
NO (1) NO20031853L (es)
OA (1) OA12529A (es)
PA (1) PA8531401A1 (es)
PE (1) PE20020589A1 (es)
PL (1) PL366201A1 (es)
SK (1) SK4972003A3 (es)
SV (1) SV2003000705A (es)
TN (1) TNSN01149A1 (es)
WO (1) WO2002034753A2 (es)
ZA (1) ZA200302190B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DE60236851D1 (en) 2001-02-14 2010-08-12 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
JP2004518726A (ja) 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ベンゾチアジアジンマトリックスメタロプロテイナーゼ阻害剤
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003228701A1 (en) * 2002-04-25 2003-11-10 Bristol-Myers Squibb Company Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
MXPA04008563A (es) * 2002-04-26 2004-12-06 Pfizer Prod Inc Inhibidores de metaloproteinasa de triaril-oxi-aril-espiro-pirimidina-2,4,6-triona.
MXPA04010545A (es) * 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de heteroariloxi-aril-espiero-pirimidina-2,4,6-triona n-sustituida.
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
BR0313384A (pt) 2002-08-13 2005-07-12 Warner Lambert Co Derivados de cromona como inibidores de metaloproteinases de matriz
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
WO2005097133A1 (en) * 2004-04-01 2005-10-20 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
CN102285934B (zh) * 2009-01-08 2013-08-14 四川大学 螺环二烯酮衍生物及其制备方法和用途
NO2930176T3 (es) * 2012-12-10 2018-07-07
KR101594506B1 (ko) * 2014-03-20 2016-02-17 한국화학연구원 골 관련 질환 치료용 조성물
EP3153166B1 (en) 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN110092790B (zh) * 2019-06-11 2020-07-24 东北农业大学 一种生物碱类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714093A (en) * 1970-05-19 1973-01-30 American Home Prod Spiro [heterocycloalkyl-2'(1'h)-quinazoline]-4'(3'h)-ones
ES2247707T3 (es) * 1997-06-21 2006-03-01 Roche Diagnostics Gmbh Derivados del acido barbiturico con actividad antimetastasica y antitumoral.
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
HN2000000137A (es) * 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas

Also Published As

Publication number Publication date
CZ20031083A3 (cs) 2004-03-17
HUP0301577A3 (en) 2006-02-28
NO20031853L (no) 2003-06-23
PL366201A1 (en) 2005-01-24
KR20040004412A (ko) 2004-01-13
CA2425283A1 (en) 2002-05-02
ECSP034567A (es) 2003-06-25
BG107653A (bg) 2003-12-31
BR0114913A (pt) 2003-07-01
CN1501937A (zh) 2004-06-02
SK4972003A3 (en) 2004-05-04
HRP20030332A2 (en) 2003-06-30
AP2001002318A0 (en) 2001-12-31
NO20031853D0 (no) 2003-04-24
AU2002210813A1 (en) 2002-05-06
GT200100213A (es) 2002-07-03
MXPA03003735A (es) 2003-07-28
WO2002034753A3 (en) 2002-08-15
OA12529A (en) 2006-06-02
SV2003000705A (es) 2003-01-13
IL154948A0 (en) 2003-10-31
EA005762B1 (ru) 2005-06-30
PA8531401A1 (es) 2003-06-30
HUP0301577A2 (hu) 2003-11-28
WO2002034753A2 (en) 2002-05-02
ZA200302190B (en) 2004-04-28
EE200300196A (et) 2003-10-15
MA26957A1 (fr) 2004-12-20
EP1332146A2 (en) 2003-08-06
EA200300306A1 (ru) 2003-08-28
TNSN01149A1 (fr) 2005-11-10
PE20020589A1 (es) 2002-07-06
HN2001000244A (es) 2003-11-07
JP2004518635A (ja) 2004-06-24
IS6762A (is) 2003-03-27

Similar Documents

Publication Publication Date Title
AR035069A1 (es) Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
CO5261625A1 (es) Novedoso derivados fenilheteroalquilamina, procesos para su prepraracion, coposiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
SE9702799D0 (sv) New compounds
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
DE69231298T2 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
UA27901C2 (uk) Похідні 7-(2-аміноетил)бензотіазолону, що проявляють агоністичну активність по відношенню до бета2-адренорецепторів, фармацевтична композиція, спосіб їх отримання та проміжні сполуки
AR040928A1 (es) Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
NO923199L (no) Terapeutiske forbindelser
RU2004122427A (ru) Пирролидин-2-оны в качестве ингибиторов фактора ха
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten
UY28688A1 (es) Derivados de amida
PT1412332E (pt) Derivados de quinolina e sua utilizacao como agentes antitumorais
PT871626E (pt) Triazolonas utilizadas como inibidores de sintese da apoliproteina b
AR038094A1 (es) Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica
FI923662A (fi) Terapeutiska medel
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE265423T1 (de) Neue phenylheteroalkylamin-derivate
GB0030729D0 (en) Substituted-4-Quinolones
DE60103035D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom
AR035219A1 (es) Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto

Legal Events

Date Code Title Description
FB Suspension of granting procedure